Want to see KR:005690 full AI Analyst Report?
Pharmicell Co., Ltd (005690) AI Stock Analysis
Pharmicell Co., Ltd
(Korea Exchange:005690)
The score is primarily supported by strong current profitability and a healthy, low-leverage balance sheet. This is tempered by weak technicals (bearish momentum and price below key moving averages) and some concern around cash-flow and revenue-growth consistency, while valuation is reasonable but the dividend yield offers limited support.
Pharmicell Co., Ltd (005690) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 564.04B
- Dividend Yield
- 0.53%
- Average Volume (3M)
- 1.10M
- Price to Earnings (P/E)
- 12.1
- Beta (1Y)
- 0.62
- Revenue Growth
- 51.28%
- EPS Growth
- 124.70%
- Country
- KR
- Employees
- 186
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Pharmicell Co., Ltd Business Overview & Revenue Model
Company Description
Headquartered in Seoul, South Korea, Pharmicell Co., Ltd. is a biopharmaceutical company established in 2002, actively developing and marketing stem cell treatments across South Korea and globally. The firm operates through two primary segments: Biop...
Pharmicell Co., Ltd Financial Statement Overview
Summary
Strong profitability step-up in TTM with very high margins (gross ~44%, operating ~32%, net ~34%) and meaningfully higher net income, supported by low leverage (debt-to-equity ~0.18) and strong ROE (~36%). Offsetting factors are inconsistent top-line growth (negative in 2023; modest in 2024–2025) and uneven free-cash-flow history, with TTM FCF down ~18% and prior years showing volatility/negative FCF.
Income Statement
86Very PositiveBalance Sheet
82Very PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 135.94B | 114.06B | 64.85B | 56.23B | 60.18B | 51.81B |
| Gross Profit | 59.93B | 50.01B | 21.33B | 14.96B | 23.82B | 23.17B |
| EBITDA | 47.00B | 36.81B | 9.43B | 8.44B | 8.90B | 12.87B |
| Net Income | 46.57B | 40.33B | 6.33B | 3.58B | 8.26B | 9.45B |
Balance Sheet | ||||||
| Total Assets | 184.15B | 157.42B | 99.26B | 92.52B | 112.69B | 95.81B |
| Cash, Cash Equivalents and Short-Term Investments | 65.67B | 56.84B | 11.20B | 14.03B | 25.96B | 36.24B |
| Total Debt | 25.53B | 14.59B | 686.00M | 3.03B | 16.84B | 17.25B |
| Total Liabilities | 40.78B | 33.54B | 12.83B | 12.12B | 32.98B | 30.46B |
| Stockholders Equity | 143.37B | 123.88B | 86.44B | 80.40B | 76.66B | 63.87B |
Cash Flow | ||||||
| Free Cash Flow | 26.12B | 33.60B | -839.98M | 5.79B | -11.04B | -9.54B |
| Operating Cash Flow | 41.02B | 41.05B | 3.50B | 11.81B | 7.91B | -5.22B |
| Investing Cash Flow | -68.72B | -32.33B | -6.80B | 5.92B | -20.53B | -9.35B |
| Financing Cash Flow | 13.71B | 12.48B | -3.22B | -18.71B | -269.81M | 18.51B |
Pharmicell Co., Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:005690, the sentiment is Negative. The current price of 9400.00 is below the 20-day moving average (MA) of 11071.00, below the 50-day MA of 11223.60, and below the 200-day MA of 13752.40, indicating a bearish trend. The MACD of -546.22 indicates Positive momentum. The RSI at 34.40 is Neutral, neither overbought nor oversold. The STOCH value of 21.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:005690.
Pharmicell Co., Ltd Peers Comparison
Overall Rating
- KR:00569070Outperform
KR:95021045Neutral
KR:19980043Neutral
KR:30244043Neutral
KR:01100041Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KR:005690 | 70Outperform | KRW 563.92B | 12.12 | ― | 0.53% | 51.28% | 124.70% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:950210 | 45Neutral | KRW 241.59B | -2.61 | ― | ― | 84.72% | -480.97% |
| KR:199800 | 43Neutral | KRW 285.35B | -16.97 | ― | ― | 116.74% | -482.50% |
| KR:302440 | 43Neutral | KRW 2.57T | -30.71 | ― | ― | 23.25% | -58.35% |
| KR:011000 | 41Neutral | KRW 48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:005690 | Pharmicell Co., Ltd | 9400.00 | -8738.31 | -48.18% | |
| KR:011000 | GeneOne Life Science, Inc. | 2670.00 | -7555.00 | -73.89% | |
| KR:052020 | STCube, Inc. | 6580.00 | -2150.00 | -24.63% | |
| KR:199800 | ToolGen Incorporated | 29200.00 | -25684.21 | -46.80% | |
| KR:302440 | SK bioscience Co.,Ltd. | 32750.00 | -18050.00 | -35.53% | |
| KR:950210 | Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh | 4020.00 | -8280.00 | -67.32% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026